#Johnson & Johnson

[ follow ]
#johnson--johnson

J&J Backs Down From 340B Rebates, But Maintains They're 'Legally Permissible' Per Statute - MedCity News

Johson & Johnson's attempted changes to the 340B program sparked controversy and scrutiny, emphasizing the program's role in providing drug discounts for underserved communities.

Roy Butler inquest: Covid vaccine firm says 'insufficient evidence' for link to fatal brain bleeds

The Janssen vaccine was linked to multiple cases of brain bleeds, but Johnson & Johnson found insufficient evidence to establish a causal relationship.

Roy Butler inquest: Covid vaccine firm warns 'insufficient evidence' for link to fatal brain bleeds

Johnson & Johnson claims insufficient evidence links brain bleeds to their vaccine, despite some incidents reported after vaccination.

Prediction: Johnson & Johnson's Dividend Payouts Will Increase in 2025

Dividend stocks provide investors with consistent income and long-term total returns from dividends and capital gains.

Johnson & Johnson's $390 billion dilemma

Johnson & Johnson leads in healthcare stocks with $390 billion market cap, but growth has been modest.
The company is focused on expanding through acquisitions and internal development of new products.

The Morning Risk Report: Johnson & Johnson to Pay $700 Million to Settle Baby Powder Probe

Johnson & Johnson has tentatively agreed to pay about $700 million to settle an investigation into the marketing of its talcum-based baby powder.
The proposed settlement with states would only address a small portion of the litigation over the safety and marketing of J&J's talcum powders.

J&J Backs Down From 340B Rebates, But Maintains They're 'Legally Permissible' Per Statute - MedCity News

Johson & Johnson's attempted changes to the 340B program sparked controversy and scrutiny, emphasizing the program's role in providing drug discounts for underserved communities.

Roy Butler inquest: Covid vaccine firm says 'insufficient evidence' for link to fatal brain bleeds

The Janssen vaccine was linked to multiple cases of brain bleeds, but Johnson & Johnson found insufficient evidence to establish a causal relationship.

Roy Butler inquest: Covid vaccine firm warns 'insufficient evidence' for link to fatal brain bleeds

Johnson & Johnson claims insufficient evidence links brain bleeds to their vaccine, despite some incidents reported after vaccination.

Prediction: Johnson & Johnson's Dividend Payouts Will Increase in 2025

Dividend stocks provide investors with consistent income and long-term total returns from dividends and capital gains.

Johnson & Johnson's $390 billion dilemma

Johnson & Johnson leads in healthcare stocks with $390 billion market cap, but growth has been modest.
The company is focused on expanding through acquisitions and internal development of new products.

The Morning Risk Report: Johnson & Johnson to Pay $700 Million to Settle Baby Powder Probe

Johnson & Johnson has tentatively agreed to pay about $700 million to settle an investigation into the marketing of its talcum-based baby powder.
The proposed settlement with states would only address a small portion of the litigation over the safety and marketing of J&J's talcum powders.
morejohnson--johnson

Johnson & Johnson's prescription for growth | Entrepreneur

Johnson & Johnson is projecting a revenue surge of 5-6% in 2024.
The company's strategic acquisitions demonstrate a commitment to growth in the MedTech division.

IBM, Johnson & Johnson Hit With Second Health Data Breach Suit

IBM and Johnson & Johnson are facing a proposed class action lawsuit over a data breach that potentially exposed the personal health information of over half a million people.
The lawsuit alleges negligence on the part of both companies regarding the safety of sensitive health records shared with J&J that were exposed as a result of the data breach at IBM.
The breach affected J&J's Janssen CarePath system, a patient support program that holds users' prescription medication data.
[ Load more ]